Navigation Links
DNA nanotechnology breakthrough offers promising applications in medicine
Date:3/17/2010

This release is available in French.

A team of McGill Chemistry Department researchers led by Dr. Hanadi Sleiman has achieved a major breakthrough in the development of nanotubes tiny "magic bullets" that could one day deliver drugs to specific diseased cells. Sleiman explains that the research involves taking DNA out of its biological context. So rather than being used as the genetic code for life, it becomes a kind of building block for tiny nanometre-scale objects.

Using this method, the team created the first examples of DNA nanotubes that encapsulate and load cargo, and then release it rapidly and completely when a specific external DNA strand is added. One of these DNA structures is only a few nanometres wide but can be extremely long, about 20,000 nanometres. (A nanometre is one-10,000th the diameter of a human hair.)

Until now, DNA nanotubes could only be constructed by rolling a two-dimensional sheet of DNA into a cylinder. Sleiman's method allows nanotubes of any shape to be formed and they can either be closed to hold materials or porous to release them. Materials such as drugs could then be released when a particular molecule is present.

One of the possible future applications for this discovery is cancer treatment. However, Sleiman cautions, "we are still far from being able to treat diseases using this technology; this is only a step in that direction. Researchers need to learn how to take these DNA nanostructures, such as the nanotubes here, and bring them back to biology to solve problems in nanomedicine, from drug delivery, to tissue engineering to sensors," she said.

The team's discovery was published on March 14, 2010 in Nature Chemistry. The research was made possible with funding from the National Science and Engineering Research Council and the Canadian Institute for Advanced Research.


'/>"/>

Contact: William Raillant-Clark
william.raillant-clark@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Page: 1

Related biology news :

1. Vigilance needed in nanotechnology
2. Engineers explore environmental concerns of nanotechnology
3. Conference to discuss future of nanotechnology enabled sensors
4. Novel nanotechnology heals abscesses caused by resistant staph bacteria
5. Step forward for nanotechnology: Controlled movement of molecules
6. Nanotechnology and synthetic biology: What does the American public think?
7. New DNA test uses nanotechnology to find early signs of cancer
8. Singapore nanotechnology combats fatal brain infections
9. University awarded £1.7M to develop nanotechnology for use in health care
10. Nanotechnology holds promise for STD drug delivery
11. Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
Breaking Biology Technology: